3.735
price up icon1.77%   0.055
after-market Handel nachbörslich: 3.74 0.005 +0.13%
loading
Schlusskurs vom Vortag:
$3.68
Offen:
$3.7
24-Stunden-Volumen:
2.82M
Relative Volume:
0.53
Marktkapitalisierung:
$1.03B
Einnahmen:
$194.75M
Nettoeinkommen (Verlust:
$-51.26M
KGV:
-13.34
EPS:
-0.28
Netto-Cashflow:
$-23.38M
1W Leistung:
+5.20%
1M Leistung:
+30.94%
6M Leistung:
+94.04%
1J Leistung:
+305.00%
1-Tages-Spanne:
Value
$3.61
$3.755
1-Wochen-Bereich:
Value
$3.48
$3.87
52-Wochen-Spanne:
Value
$0.91
$4.0758

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Name
Firmenname
Akebia Therapeutics Inc
Name
Telefon
617-871-2098
Name
Adresse
245 FIRST STREET, CAMBRIDGE, MA
Name
Mitarbeiter
181
Name
Twitter
@akebiatx
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
AKBA's Discussions on Twitter

Vergleichen Sie AKBA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
AKBA
Akebia Therapeutics Inc
3.735 1.03B 194.75M -51.26M -23.38M -0.28
Drug Manufacturers - Specialty & Generic icon
RGC
Regencell Bioscience Holdings Ltd
20.20 303.95B 0 -5.87M -767.30K -0.45
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
155.80 74.39B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.42 48.97B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.07 47.39B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.57 20.17B 16.54B -1.64B 749.00M -1.45

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-04 Fortgesetzt H.C. Wainwright Buy
2025-04-28 Eingeleitet Leerink Partners Outperform
2025-04-01 Eingeleitet Jefferies Buy
2023-11-29 Fortgesetzt BTIG Research Buy
2023-08-28 Hochstufung H.C. Wainwright Neutral → Buy
2023-05-31 Hochstufung Piper Sandler Neutral → Overweight
2022-03-31 Herabstufung H.C. Wainwright Buy → Neutral
2022-03-31 Herabstufung Mizuho Buy → Neutral
2022-03-31 Herabstufung Needham Buy → Hold
2022-03-31 Herabstufung Piper Sandler Overweight → Neutral
2021-03-08 Eingeleitet Cantor Fitzgerald Overweight
2021-01-29 Herabstufung JP Morgan Neutral → Underweight
2019-11-14 Bestätigt Needham Buy
2019-08-06 Bestätigt H.C. Wainwright Buy
2019-07-11 Bestätigt H.C. Wainwright Buy
2019-05-02 Eingeleitet JP Morgan Overweight
2019-03-20 Eingeleitet Citigroup Neutral
2018-09-07 Fortgesetzt Morgan Stanley Equal-Weight
2018-08-10 Bestätigt Needham Buy
2018-06-06 Bestätigt H.C. Wainwright Buy
2017-12-19 Eingeleitet Piper Jaffray Overweight
2017-12-07 Eingeleitet BTIG Research Buy
2017-09-15 Eingeleitet RBC Capital Mkts Sector Perform
2017-07-10 Bestätigt H.C. Wainwright Buy
2017-04-27 Bestätigt H.C. Wainwright Buy
2017-04-27 Bestätigt Needham Buy
2016-12-27 Bestätigt H.C. Wainwright Buy
2016-12-20 Bestätigt JMP Securities Mkt Outperform
2016-11-15 Eingeleitet Aegis Capital Buy
2016-09-29 Eingeleitet Brean Capital Buy
2016-03-16 Bestätigt Needham Buy
2016-01-21 Eingeleitet Credit Suisse Neutral
Alle ansehen

Akebia Therapeutics Inc Aktie (AKBA) Neueste Nachrichten

pulisher
Jun 18, 2025

There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 34% Share Price Rise - simplywall.st

Jun 18, 2025
pulisher
Jun 17, 2025

AVEROA - The Pharma Letter

Jun 17, 2025
pulisher
Jun 16, 2025

AVEROA receives European marketing authorization for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD) - The Manila Times

Jun 16, 2025
pulisher
Jun 16, 2025

AVEROA receives European marketing authorization for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD) - GlobeNewswire Inc.

Jun 16, 2025
pulisher
Jun 13, 2025

Akebia Therapeutics expands stock incentive plan - Investing.com Australia

Jun 13, 2025
pulisher
Jun 13, 2025

Akebia Therapeutics expands stock incentive plan By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Akebia Therapeutics Approves Stock Plan Amendment at Meeting - TipRanks

Jun 13, 2025
pulisher
Jun 07, 2025

Akebia Therapeutics: Stock Is Trading At Fair Value Amid Robust Drug Adoption Into 2026 - Seeking Alpha

Jun 07, 2025
pulisher
Jun 07, 2025

Day 7 of Gains Streak for Akebia Therapeutics Stock with 38% Return (vs. 109% YTD) [6/6/2025] - Trefis

Jun 07, 2025
pulisher
Jun 06, 2025

H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating - MSN

Jun 06, 2025
pulisher
Jun 06, 2025

Akebia Therapeutics at Jefferies Conference: Strategic Growth Insights By Investing.com - Investing.com Canada

Jun 06, 2025
pulisher
Jun 05, 2025

Organizational Transitions, Patient Enrollment, Initiation of Clinical Programs, Financial Outlook, and Corporate UpdatesA... - ADVFN

Jun 05, 2025
pulisher
Jun 04, 2025

Akebia reports mixed results for anemia drug in global study By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Akebia Therapeutics: Finally Showing Potential, But Wait For Q2 Earnings Before Buying - Seeking Alpha

Jun 04, 2025
pulisher
Jun 04, 2025

Akebia reports mixed results for anemia drug in global study - Investing.com Australia

Jun 04, 2025
pulisher
Jun 04, 2025

Akebia Therapeutics (AKBA) Receives 'Buy' Rating from HC Wainwri - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Akebia (AKBA) Publishes Phase 3 Clinical Trial Analysis | AKBA S - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Akebia Therapeutics Announces Publication of Pre-specified Analyses on Vadadustat from Global Phase 3 Clinical Program in Journal of the American Society of Nephrology - Nasdaq

Jun 04, 2025
pulisher
Jun 04, 2025

Vadadustat U.S. Patient Data from Global Phase 3 Clinical - GlobeNewswire

Jun 04, 2025
pulisher
Jun 04, 2025

Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

H.C. Wainwright assumes coverage on Akebia Therapeutics stock with buy rating - Investing.com

Jun 04, 2025
pulisher
Jun 04, 2025

Akebia (AKBA) Receives Buy Rating with Promising Outlook for Vaf - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Akebia Ther stock soars to 52-week high, hits $3.31 By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 03, 2025

Akebia Ther stock soars to 52-week high, hits $3.31 - Investing.com Australia

Jun 03, 2025
pulisher
Jun 02, 2025

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Akebia Therapeutics Expands Team with Strategic New Hires, Grants $415,000 in Stock Options - Stock Titan

Jun 02, 2025
pulisher
May 28, 2025

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025 - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

Kidney Disease Leader Akebia Therapeutics Sets Major Investor Presentation at Jefferies Healthcare Conference - Stock Titan

May 28, 2025
pulisher
May 28, 2025

Akebia’s patent for Anemia therapy gets fresh blood from Court - BananaIP

May 28, 2025
pulisher
May 27, 2025

Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025 - GlobeNewswire

May 27, 2025
pulisher
May 27, 2025

Akebia Unveils Critical Cardiovascular Safety Analysis for Vadadustat in Dialysis Patients at ERA Congress - Stock Titan

May 27, 2025
pulisher
May 25, 2025

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

May 25, 2025
pulisher
May 24, 2025

Northern Trust Corp Has $3.20 Million Stock Position in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World

May 24, 2025
pulisher
May 20, 2025

Akebia Therapeutics stock soars to 52-week high of $2.91 By Investing.com - Investing.com India

May 20, 2025
pulisher
May 20, 2025

Akebia Therapeutics at H.C. Wainwright Conference: Vafseo’s Strategic Launch By Investing.com - Investing.com Canada

May 20, 2025
pulisher
May 20, 2025

Akebia Therapeutics stock soars to 52-week high of $2.91 - Investing.com Australia

May 20, 2025
pulisher
May 18, 2025

Certain Common Stock of Akebia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2025. - marketscreener.com

May 18, 2025
pulisher
May 18, 2025

Certain Stock Options of Akebia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2025. - marketscreener.com

May 18, 2025
pulisher
May 18, 2025

Certain Rights of Akebia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2025. - marketscreener.com

May 18, 2025
pulisher
May 18, 2025

Certain Warrants of Akebia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2025. - marketscreener.com

May 18, 2025
pulisher
May 16, 2025

Price T Rowe Associates Inc. MD Has $263,000 Holdings in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World

May 16, 2025
pulisher
May 15, 2025

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Sold by Voya Investment Management LLC - Defense World

May 15, 2025
pulisher
May 14, 2025

Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results - GuruFocus

May 14, 2025

Finanzdaten der Akebia Therapeutics Inc-Aktie (AKBA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Akebia Therapeutics Inc-Aktie (AKBA) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Malabre Richard C
SVP, Chief Accounting Officer
Jun 09 '25
Sale
4.01
15,000
60,150
266,914
Malabre Richard C
SVP, Chief Accounting Officer
Jun 04 '25
Sale
3.53
13,334
47,069
266,914
Butler John P.
CEO and President
Mar 03 '25
Sale
1.83
46,409
84,928
2,557,921
Burke Steven Keith
SVP, Chief Medical Officer
Mar 03 '25
Sale
1.83
7,144
13,074
809,090
$14.14
price up icon 2.29%
$8.91
price up icon 0.11%
$128.26
price up icon 0.23%
$287.74
price up icon 0.97%
drug_manufacturers_specialty_generic RDY
$15.56
price up icon 0.39%
$16.66
price down icon 2.00%
Kapitalisierung:     |  Volumen (24h):